Professor vid Institutionen för farmaci, Farmakometri
Lena Friberg was in 2014 promoted to Professor in Pharmacometrics and is since 2021 Professor in Pharmacokinetics and Pharmacodynamics. Her research focuses on translation and dose optimization within oncology and infectious diseases, by advancing concepts for interpretation and integration of in vitro, in vivo and clinical data through PKPD modelling. Developed frameworks aim to make transition between drug development stages more efficient while considering both desired and adverse effects.
Akademiska meriter: FarmD, Docent (PhD Associate professor)
Nyckelord: immune system cancer antibiotics antibiotic resistance preclinical translational research non-linear mixed effects modelling pharmacokinetics pharmacometrics pharmacodynamics translational medicine modeling and simulation anticancer therapy bacterial infections drug development drug usage vaccines
Lena was promoted to professor in Pharmacometrics in 2014 and is since 2021 professor in Pharmacokinetics and Pharmacodynamics. She holds a Master degree in Pharmaceutical Sciences and obtained a PhD in Pharmacokinetics and Drug Therapy from Uppsala University in 2003. During 2003-2008 she was supported by a personal grant from Knut & Alice Wallenberg foundation as a postdoc research fellow at the University of Queensland, Australia, and as a researcher at Uppsala University. In 2007 she became Docent (Associate professor) in Pharmacometrics.
Dr Friberg's research focuses on development of pharmacokinetic (PK) and pharmacodynamic (PD) models of desired effects and adverse events, based on experimental data. The research team drives development of models and methods that facilitates the transition between various phases of drug development through more precise predictions. Dosing strategies are optimized based on preclinical (in vitro and in vivo) information, as well as patient characteristics and measurements (e.g. biomarkers, symptoms, side-effects). The main disease areas include oncology, infection and immunology, for which efforts are also made to optimize experimental models and protocols.
Dr Friberg has published over 150 peer-reviewed research articles and has an h-index of 48. She has mentored 11 students to PhD degree as main supervisor, and an additional 9 as co-supervisor, and is currently the main supervisor of 9 PhD students and mentor of 3 Postdocs and early researchers. She holds competitive grants from Swedish Research Council, Swedish Cancer Society, Uppsala Antibiotic Center, Innovative Medicines Initiative (IMI), IMI 2 Join Undertaking and Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN). Through IMI-ENABLE she works as a PK and PD expert and PI in the preclinical and early clinical development of novel antibiotics, and in IMI-COMBINE she is leading the WP on standardization of animal infection models. She is also WP-leader and Scientific director of the ITN TIPAT focusing on increasing knowledge and methods to characterize host-bacteria-drug interactions. Lena has received the Giorgio Segré Prize from EUFEPS for “distinct research in the Pharmacokinetic-Pharmacodynamic area” and been appointed "Key Scientist" by Vinnova/BioSweden. In 2016 she received the Innovation award in Pharmacometrics from ISoP. She is since 2012 the deputy Editor-in-chief of the journal CPT: Pharmacometrics & Systems Pharmacology and since 2020 Associate Editor of Frontiers Pharmacology: Translational Research.
Dr Friberg is also heading the teaching unit Pharmacokinetics, Pharmacotherapy and Clinical Pharmacy. She is teaching undergraduate and master students in Pharmacokinetics, Pharmacodynamics, Pharmacometrics, Antimicrobial ADME & PKPD and Drug development. She also gives courses to professionals on PKPD-modeling and the use of translation for improved drug development.
Kontakta katalogansvarig vid den aktuella organisationen (institution eller motsv.) för att rätta ev. felaktigheter.